IRF2 and neoplasm: To validate whether IRF2binds to the mouse cd279 promoter, we treated RAW264.7 cells with recombinant IFNβ and treated CT26 tumor-bearing mice with IFNBCOL01, then performed ChIP analysis using an IRF2-specific antibody and PCR primers that covered the promoters approximately from −2000 to +2000 relative to the transcription start site of the mouse cd279 (Figure 5B).